Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rhabdoid Tumor 1 Rectal Neoplasms 1 Lung Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Chordoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Advanced Solid Malignancies 1 Advanced Liver Cancers 1

Interventions

pembrolizumab 28 Paclitaxel 24 Carboplatin 19 Bevacizumab 14 Specimen Handling 13 Magnetic Resonance Spectroscopy 10 Doxorubicin 8 Cisplatin 8 Biopsy 8 olaparib 7 lenvatinib 7 Taxes 7 Letrozole 7 Megestrol Acetate 6 Fulvestrant 6 durvalumab 5 dostarlimab 5 Nivolumab 5 Medroxyprogesterone Acetate 5 Gemcitabine 5 trastuzumab deruxtecan 4 abemaciclib 4 X-Rays 4 Trastuzumab 4 Tirzepatide 4 Progestins 4 Oxaliplatin 4 Immunoglobulin G 4 Fluorouracil 4 Docetaxel 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Endometrial Neoplasms × Tiragolumab × 90 days × Clear all

NCT04486352 2026-04-01

EndoMAP

Alliance Foundation Trials, LLC.

Phase 1/2 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡